{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:36:23Z","timestamp":1790116583807,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116060"],"award-info":[{"award-number":["116060"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hertie Institute for Clinical Brain Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00401-021-02400-5","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T23:19:41Z","timestamp":1640647181000},"page":"287-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["CSF p-tau increase in response to A\u03b2-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles"],"prefix":"10.1007","volume":"143","author":[{"given":"Stephan A.","family":"Kaeser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"H\u00e4sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Bottelbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Theunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mercken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-1072","authenticated-orcid":false,"given":"Mathias","family":"Jucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"2400_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS  et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26:398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z","journal-title":"Nat Med"},{"key":"2400_CR2","doi-asserted-by":"publisher","first-page":"7969","DOI":"10.1073\/pnas.1001056107","volume":"107","author":"J Coomaraswamy","year":"2010","unstructured":"Coomaraswamy J, Kilger E, Wolfing H, Sch\u00e4fer C, Kaeser SA,  Wegenast-Braun BM et al (2010) Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 107:7969\u20137974. https:\/\/doi.org\/10.1073\/pnas.1001056107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2400_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"2400_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0002-9440(10)63993-4","volume":"158","author":"JL Holton","year":"2001","unstructured":"Holton JL, Ghiso J, Lashley T, Rostagno A, Guerin CJ, Gibb G et al (2001) Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol 158:515\u2013526. https:\/\/doi.org\/10.1016\/S0002-9440(10)63993-4","journal-title":"Am J Pathol"},{"key":"2400_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/jnen\/61.3.254","volume":"61","author":"JL Holton","year":"2002","unstructured":"Holton JL, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin CJ  et al (2002) Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol 61:254\u2013267. https:\/\/doi.org\/10.1093\/jnen\/61.3.254","journal-title":"J Neuropathol Exp Neurol"},{"key":"2400_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo C, Feldman HH, Frisoni GB  et al (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539\u2013547. https:\/\/doi.org\/10.1212\/WNL.0000000000002923","journal-title":"Neurology"},{"key":"2400_CR7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC  et al (2020) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun 11:1683. https:\/\/doi.org\/10.1038\/s41467-020-15436-0","journal-title":"Nat Commun"},{"key":"2400_CR8","unstructured":"Mintun MA, Lu M, Schade AE, Dage JL, Willis BA, Brooks DA et al (2021) TRAILBLAZER-ALZ study: amyloid clearance results in a rapid and sustained reduction in plasma P217tau levels. Presented at the Alzheimer's Association International Conference (AAIC), Denver, USA and Online, July 26\u201330, 2021"},{"key":"2400_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L  et al (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940\u2013946. https:\/\/doi.org\/10.1038\/sj.embor.7400784","journal-title":"EMBO Rep"},{"key":"2400_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jalz.2016.09.005","volume":"13","author":"J Schelle","year":"2017","unstructured":"Schelle J, Hasler LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E et al (2017) Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement 13:701\u2013709. https:\/\/doi.org\/10.1016\/j.jalz.2016.09.005","journal-title":"Alzheimers Dement"},{"key":"2400_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A  et al (2021) Structure-based classification of tauopathies. Nature 598:359\u2013363. https:\/\/doi.org\/10.1038\/s41586-021-03911-7","journal-title":"Nature"},{"key":"2400_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3233\/JAD-200463","volume":"77","author":"G Triana-Baltzer","year":"2020","unstructured":"Triana-Baltzer G, Van Kolen K, Theunis C, Moughadam S, Slemmon R, Mercken M  et al (2020) Development and validation of a high sensitivity assay for measuring p217 + tau in cerebrospinal fluid. J Alzheimer\u2019s Dis 77:1417\u20131430. https:\/\/doi.org\/10.3233\/JAD-200463","journal-title":"J Alzheimer's Dis"},{"key":"2400_CR13","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.15252\/embr.201744067","volume":"18","author":"L Ye","year":"2017","unstructured":"Ye L, Rasmussen J, Kaeser SA, Marzesco AM, Obermuller U, Mahler J et al (2017) Abeta seeding potency peaks in the early stages of cerebral beta-amyloidosis. EMBO Rep 18:1536\u20131544. https:\/\/doi.org\/10.15252\/embr.201744067","journal-title":"EMBO Rep"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-021-02400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-021-02400-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-021-02400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T06:03:54Z","timestamp":1641621834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-021-02400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1007\/s00401-021-02400-5","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B., C.T. and M.M. were employees of Janssen Research and Development, LLC at the time the study was conducted. All the other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}